Last reviewed · How we verify

DBPR108 — Competitive Intelligence Brief

DBPR108 (DBPR108) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Pyruvate dehydrogenase kinase (PDK) inhibitor. Area: Metabolic disorders / Mitochondrial dysfunction.

phase 3 Pyruvate dehydrogenase kinase (PDK) inhibitor PDK (Pyruvate Dehydrogenase Kinase) Metabolic disorders / Mitochondrial dysfunction Small molecule Live · refreshed every 30 min

Target snapshot

DBPR108 (DBPR108) — National Health Research Institutes, Taiwan. DBPR108 is a small-molecule inhibitor that targets pyruvate dehydrogenase kinase (PDK) to modulate cellular metabolism and energy production.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
DBPR108 TARGET DBPR108 National Health Research Institutes, Taiwan phase 3 Pyruvate dehydrogenase kinase (PDK) inhibitor PDK (Pyruvate Dehydrogenase Kinase)
PTC923 PTC923 PTC Therapeutics phase 3 Pyruvate dehydrogenase kinase (PDK) inhibitor PDK (pyruvate dehydrogenase kinase)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Pyruvate dehydrogenase kinase (PDK) inhibitor class)

  1. National Health Research Institutes, Taiwan · 1 drug in this class
  2. PTC Therapeutics · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DBPR108 — Competitive Intelligence Brief. https://druglandscape.com/ci/dbpr108. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: